<DOC>
	<DOCNO>NCT01627067</DOCNO>
	<brief_summary>The goal clinical research study learn exemestane everolimus combine metformin help control breast cancer patient obese overweight post-menopausal hormone-receptor-positive breast cancer spread part body . Exemestane design decrease ability estrogen help cancer cell grow . This could cause cancer cell die . Metformin commonly use control blood sugar level patient diabetes . It design low insulin level , may slow stop growth breast cancer cell . Everolimus design block cell divide . This may cause cancer cell die . Everolimus may also stop growth new blood vessel help tumor grow .</brief_summary>
	<brief_title>Exemestane-RAD001-Metformin</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take exemestane everolimus tablet mouth every day . You also take tablet metformin mouth 2 time day . The drug take time day . The study drug give 28-day cycle . Study Visits : On Day 1 : - You physical exam , include measurement weight vital sign . - You ask side effect may . - You ask drug may take may take . - Your performance status record . - Blood ( 1-2 teaspoon ) draw routine test . - Blood ( 1 teaspoon ) drawn blood sugar test . If history diabetes , need fast 8 hour blood sugar test . At Weeks 4 12 : - You physical exam , include measurement vital sign . - You ask side effect may . - You ask drug may take may take . - Blood ( 1-2 teaspoon ) draw routine test . - Blood ( 1 teaspoon ) drawn blood sugar test . If history diabetes , need fast 8 hour blood sugar test . At Weeks 8 , 16 every 2 month , last dose study drug : - You physical exam , include measurement vital sign . - You ask side effect may . - You ask drug may take may take . - Blood ( 1-2 teaspoon ) draw routine test . - Blood ( 4 teaspoon ) draw biomarker testing ( week 8 , 16 24 ) . - Blood ( 1 teaspoon ) drawn blood sugar test . If history diabetes , need fast 8 hour blood sugar test . - You image scan check status disease . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Exemestane FDA approve commercially available treatment metastatic breast cancer . Metformin FDA approve commercially available treatment diabetes . Everolimus FDA approve commercially available treat metastatic breast cancer , advance kidney cancer patient certain type brain tumor . The use drug combination investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Postmenopausal overweight obese woman history biopsyproven hormone receptorpositive breast cancer clinical evidence metastatic disease . Overweight define body mass index ( BMI ) 25 29.9 kg/m2 obese define BMI &gt; /= 30 kg/m2 . Postmenopausal status define one following : ) spontaneous menses 1 year , woman &gt; /=55 year ; b ) spontaneous menses within past 1 year woman &lt; 55 year postmenopausal gonadotrophin level ( LH FSH level &gt; 40 IU/L ) postmenopausal estradiol level ( local laboratory range ) ; c ) bilateral oophorectomy . 2 . Prior hormonal therapy metastatic breast cancer allow . Patients develop progressive metastatic disease nonsteroidal aromatase inhibitor eligible . Patients develop metastatic disease receive nonsteroidal aromatase inhibitor adjuvant set eligible . 3 . One prior chemotherapy line metastatic breast cancer allow evidence progressive disease . Patients treat chemotherapy best response evidence progression eligible . 4 . Prior tamoxifen , LH/RH agonist , anastrozole letrozole therapy adjuvant and/or neoadjuvant setting allow . Prior adjuvant and/or neoadjuvant chemotherapy allow . 5 . Patients must : [ 1 ] least one lesion accurately measure least one dimension &gt; /= 20 mm conventional image technique &gt; /= 10 mm spiral CT MRI ; [ 2 ] bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease ; follow consider disease progression among patient : ) appearance one new lytic lesion bone ; b ) appearance one new lesion outside bone ; c ) unequivocal progression exist bone lesion . 6 . Localized radiotherapy , influence signal evaluable lesion , allow prior initiation study medication . 7 . ECOG performance status &lt; /= 2 . 8 . Absolute neutrophil count ( ANC ) &gt; /= 1000/microliter , platelet &gt; /= 75,000/microliter , hemoglobin &gt; /= 8.5 gm/dL ; creatinine clearance &gt; 60 mg/dL ; bilirubin &lt; 1.5 mg/dL ( &lt; /= 3 × ULN patient know Gilbert Syndrome ) ; ALT &lt; 3 x upper limit normal ( &lt; /= 5 hepatic metastasis present ) ; alkaline phosphatase &lt; 3 x upper limit normal ; calcium &lt; /= 11.0 mg/dL . 9 . Fasting serum cholesterol &lt; /= 300 mg/dl 7.75 mmol/L fast triglyceride &lt; /= 2.5 × ULN . In case one threshold exceed , patient include initiation statin therapy mention value achieve . 10 . Bisphosphonate treatment permit management bone loss and/or bone metastasis . 11 . Patients must competent give inform consent state understand investigational nature propose treatment . 1 . HER2overexpressing breast cancer ( IHC 3+ stain situ hybridization positive ) . 2 . Diabetes mellitus active treatment hemoglobin A1C &gt; /= 6.5 % random plasma glucose &gt; 200 mg/dL patient without know diabetes . 3 . Treatment metformin 30 day prior enrollment . 4 . Known hypersensitivity intolerance metformin . 5 . Previous treatment exemestane mTOR inhibitor . 6 . Known hypersensitivity mTOR inhibitor , e.g . sirolimus ( rapamycin ) . 7 . History acromegaly , Cushing 's syndrome , Cushing 's disease , Addison 's disease ( treat untreated ) . 8 . Patients unstable angina , uncontrolled ischemic cardiac disease symptomatic congestive heart failure ( e.g . Class III IV New York Heart Association 's Functional Classification ) . 9 . Other investigational drug within past 3 week concurrently . 10 . Patients know chronic liver disease ( e.g. , chronic active hepatitis , cirrhosis ) . 11 . Another malignancy within 5 year prior registration , exception adequately treat insitu carcinoma cervix , uteri , basal squamous cell carcinoma nonmelanomatous skin cancer . 12 . Radiotherapy within four week prior registration except case localize radiotherapy analgesic purpose lytic lesion risk fracture complete within two week prior registration . Patients must recover radiotherapy toxicity . 13 . History brain central nervous system metastasis . 14 . Bilateral diffuse lymphangitic carcinomatosis . 15 . Presence lifethreatening metastatic visceral disease , define extensive hepatic involvement , degree brain leptomeningeal involvement ( past present ) , symptomatic pulmonary lymphangitic spread . Subjects discrete pulmonary parenchymal metastasis eligible , provided respiratory function compromise result disease . 16 . Patients receive concomitant immunosuppressive agent chronic corticosteroid use , time study entry except case outline : Topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local injection ( e.g . intraarticular ) allow . Patients stable low dose corticosteroid least two week enrollment allow . 17 . Any severe / uncontrolled medical condition : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction &lt; /= 6 month prior enrollment , serious uncontrolled cardiac arrhythmia ; Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN ; Acute chronic , active infectious disorder ( except Hep B Hep C positive patient ) nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy ; Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) ; Active skin , mucosa , ocular GI disorder Grade &gt; 1 18 . Significant symptomatic deterioration lung function . If clinically indicate , pulmonary function test include measure predict lung volume , DLco , O2 saturation rest room air consider exclude restrictive pulmonary disease , pneumonitis pulmonary infiltrates . 19 . Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A ( Rifabutin , Rifampicin , Clarithromycin , Ketoconazole , Itraconazole , Voriconazole , Ritonavir , Telithromycin ) within last 5 day prior registration .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Hormone Receptor Positive Metastatic Breast Cancer</keyword>
	<keyword>Hormone-sensitive</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Body Mass Index</keyword>
	<keyword>BMI</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>RAD001</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Aromasin</keyword>
	<keyword>Metformin</keyword>
</DOC>